The Use of Melatonin for Delirium Prevention in Medically Hospitalized Patients
Key facts
- Who runs it
- Sultan Qaboos University
- Where
- Oman1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 240 people, planned
- Started
- 30 Sept 2024
- Planned end
- Jun 2025
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Intervention 1
- Intervention 2
- Control
- Record updated
- 14 January 2025
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patient aged 65 years and above acutely admitted under the care of General Internal Medicine Unit
Who cannot take part
- If enteral medications are not allowed due to unavailability of nasogastric tube
- Patient on strong cytochrome P450 1A2 (CYP1A2) inhibitors (namely: fluvoxamine and viloxazine)
- If enteral medications are contraindicated due to gastrointestinal conditions
- Patient with active alcohol drinking or admitted with alcohol withdrawal syndrome
- Patients with the following autoimmune diseases (Rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus)
- Allergy to melatonin
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (liver function tests) > 3 times the upper limit of normal
- Patients admitted to the ward, however meeting requirement for vasopressors or non-invasive ventilation
- Patient admitted through emergency to Intensive Care Unit (ICU) or High Dependency Unit (HDU)
- Aphasic patients
- Patients with language barriers
- Already taking melatonin or ramelteon at the time of randomization
- Presence of delirium at the time of randomization
- Subject or proxy unable to provide informed consent within 24 hours of admission
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The high prevalence of delirium in hospitalized older adults, with significant associated morbidity and mortality, emphasize the need for effective prevention strategies. Limited trials have explored melatonin's potential in preventing delirium among patients admitted to general medical wards. Previous trials on melatonin's preventive role in medical wards had limitations, necessitating a robust, double-blinded, placebo-controlled design with a larger sample size. This randomized, double-blind study of melatonin versus placebo aims to investigate the efficacy of melatonin, a neurohormone regulating the sleep-wake cycle, in preventing delirium among medically hospitalized patients aged 65 or older. Given the high prevalence of delirium in this population and its association with adverse outcomes, the study seeks to contribute valuable insights into an effective preventive strategy.
The 3 groups in the trial
- Melatonin 5mg/dayTreatment being tested
Intervention group 1: Melatonin 5mg/day * Study drug will be given at 20:00 - 22:00 daily, starting on the day of enrolment until discharge, death, or up to 5 days as most medically hospitalised patients at great risk of delirium in the first few days of admission.(20) * The study medication will be given by mouth or if needed, via the feeding tube followed by a flush with 20mL water.
Treatment: Intervention 1
- Melatonin 8 mg/dayTreatment being tested
Intervention group 2:Study drug will be given at 20:00 - 22:00 daily, starting on the day of enrolment until discharge, death, or up to 5 days as most medically hospitalised patients at great risk of delirium in the first few days of admission.(20) • The study medication will be given by mouth or if needed, via the feeding tube followed by a flush with 20mL water.
Treatment: Intervention 2
- PlaceboPlacebo, for comparison
* Study drug will be given at 20:00 - 22:00 daily, starting on the day of enrolment until discharge, death, or up to 5 days as most medically hospitalised patients at great risk of delirium in the first few days of admission. (20) * The study medication will be given by mouth or if needed, via the feeding tube followed by a flush with 20mL water.
Treatment: Control
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Melatonin Versus Placebo for Prevention of Delirium Among Medically Hospitalized Patients: Study Protocol for a Single-Center, Double-Blinded, Randomised Controlled Trial
- Publications
- Effect of melatonin versus placebo for the prevention of delirium among medically hospitalised older patients: a double-blinded randomised controlled trial (project RESTORE).BMJ open, 2026
- Effect of melatonin versus placebo for prevention of delirium among medically hospitalised patients: study protocol for a single-centre, double-blinded, randomised controlled trial (project RESTORE).BMJ open, 2025
- Record updated
- 14 January 2025